Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Adagene ( (ADAG) ) has issued an update.
On April 2, 2026, Adagene reported updated interim data from a Phase 1b/2 study of its masked anti-CTLA-4 antibody muzastotug in combination with pembrolizumab in advanced microsatellite-stable colorectal cancer patients without liver metastases, based on a January 24, 2026 data cut. The FDA has granted Fast Track designation to this combination for adults with microsatellite-stable metastatic colorectal cancer lacking active liver metastases, underscoring its potential in a population largely unresponsive to current immunotherapies.
The latest efficacy readout showed dose-dependent benefits, with the 20 mg/kg cohorts achieving a 31% overall response rate and markedly prolonged median progression-free survival of 15.4 months in the loading-dose regimen, while safety remained manageable with low discontinuation, no dose-limiting toxicities and no Grade 4 or 5 treatment-related events. Adagene also announced a new clinical collaboration with Incyte to test muzastotug with Incyte’s TGFβR2×PD-1 bispecific INCA33890 in third-line microsatellite-stable colorectal cancer, reinforcing muzastotug’s positioning as a potential backbone therapy in next-generation immuno-oncology combinations and broadening its strategic footprint through multiple partnered trials.
The most recent analyst rating on (ADAG) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Adagene stock, see the ADAG Stock Forecast page.
Spark’s Take on ADAG Stock
According to Spark, TipRanks’ AI Analyst, ADAG is a Neutral.
The score is held back primarily by very weak financial performance (sharp revenue decline, large losses, and negative/worsening cash flows). Technicals are a key offset with an established uptrend and positive momentum, while valuation remains constrained by negative earnings and no stated dividend yield.
To see Spark’s full report on ADAG stock, click here.
More about Adagene
Adagene Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based cancer immunotherapies. Using its Dynamic Precision Library platform and SAFEbody precision masking technology, the company designs antibodies intended to improve safety and expand the therapeutic index, with a lead program, muzastotug (ADG126), targeting CTLA-4 in metastatic microsatellite-stable colorectal cancer.
Average Trading Volume: 190,997
Technical Sentiment Signal: Buy
Current Market Cap: $217.3M
For an in-depth examination of ADAG stock, go to TipRanks’ Overview page.